Abstract
A variety of predisposing factors have been associated with serious illness and death from COVID-19. Understanding the distribution of risks associated with these factors by local communities can provide important opportunities for targeting interventions. We characterize the distribution of risk for COVID-19 mortality for populations at large across 442 US cities, by utilizing recently published estimates of risk associated with age, gender, ethnicity, social deprivation and 12 health conditions from a very large UK-based study, combined with the information available on prevalence and co-occurrence of these factors in the US through a variety of population-based public databases. We estimate that across all the cities, an underlying weighted risk-score can identify a total of approximately 12.65 million, 4.09 million and 1.34 million individuals who are at 2−, 5− and 10-fold higher risk, respectively, compared to the average risk for the US population. The percentage of population which exceed the respective risk thresholds varies across the cities in the range (1st-99th percentile), 3.6%−20.1%, 0.7%−8.0% and 0.1%−3.2%, respectively. The percentage of deaths within a city that are expected to occur above these risk-thresholds varies in the range of 20.1%−53.5%, 8.5%−38.2% and 2.9%−25.4%, respectively. Our analysis can provide guidance to national and local policy makers regarding resources needed to protect the most vulnerable populations in these communities, and how much utility such interventions may have in reducing the total population burden of death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funding for this research came from the Bloomberg Distinguished Professorship endowment of Dr. Nilanjan Chatterjee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB and ethics committee approvals are exempted because our project does not involve human subject research and it only involves the analysis of publicly available anonymizes data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the manuscript are publically available. All codes for data management and analysis can be accessed at https://github.com/nchatterjeelab/COVID19Risk.
https://github.com/nchatterjeelab/COVID19Risk
https://www.census.gov/programs-surveys/acs
https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-04162020-1.pdf
https://chronicdata.cdc.gov/500-Cities/500-Cities-Local-Data-for-Better-Health-2019-relea/6vp6-wxuq
https://www.cdc.gov/cancer/uscs/dataviz/download_data.htm
https://www.graham-center.org/rgc/maps-data-tools/sdi/social-deprivation-index.html